1. Auflage - April 2010
87,90 Euro
2010. 332 Seiten, Hardcover
- Praktikerbuch -
ISBN-10: 0-470-04966-9
ISBN-13: 978-0-470-04966-2 - John Wiley & Sons

Preis inkl. Mehrwertsteuer zzgl. Versandkosten.





Probekapitel

Kurzbeschreibung
This book gives an expert view of how the project management approach can be taken forward by the pharmaceutical industry over the next decade. The book integrates portfolio, program, and project management processes as fundamentals for effective and efficient drug product development. This discussion has already begun at conferences, including the Drug Information Association conference on project management held in Philadelphia in February 2005, for which book editor Harpum was a co-chairperson.

Aus dem Inhalt
List of Contributors.

Acknowledgements.

Introduction.

SECTION I.

The Life Science Industry Context for Portfolio, Program, and Project Management.

Introduction.

1 A Review of Project Management in Life Science Industry Sectors (Thomas R. Dunson).

2 The Impact of Organizational Size on Drug Project Management (Eric Morfin).

3 Drug Development in Biotech and How We Can Do It Better (Susan Linna).

SECTION II.

The Portfolio, Program, and Project Management Approaches and Processes.

Introduction.

4 An Overview of the Organization and Processes of Portfolio, Program and Project Management (Pete Harpum).

5 Portfolio Management in the Pharmaceutical Industry: Balancing Corporate Need with the Reality of Delivering Products to the Market (John Bennett).

6 Program Management in Drug Development (Pauline Stewart-Long).

7 Project Control (Martin Powell).

8 Managing Uncertainty in Drug Projects (Pete Harpum and Thomas R. Dunson).

9 Managing Drug Safety Risk (Thomas R. Dunson and Eric Morfin).

10 Developing Program Strategy (Pete Harpum).

11 Project Value Management: Ensuring the Development of Added Value Drug Products (Trevor Brown and Stephen Allport).

SECTION III.

Integrating the Processes.

Introduction.

12 Integrated Business Process to Support Cross-Functional Drug Development (Martin D. Hynes III).

13 Integrated Drug Development From Cradle to Grave and From Lab to Market (Stephen Allport and Terry Cook-Davies).

14 The Development of P3M Capability in Drug Development Organizations (John Arrowsmith, Patrick Grogan and Bob Moore).

15 Implementing Portfolio, Program, and Project Management Best Practices in Drug Development Organizations (Pete Harpum, Ashley Jamieson and Inge Fisher).

Bibliography.